Umoja

Umoja Biopharma to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Retrieved on: 
Tuesday, March 19, 2024
Conference, Umoja, Immunotherapy, Autoimmunity

SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced that the Company will present a corporate overview at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024.

Key Points: 
  • SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced that the Company will present a corporate overview at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024.
  • Members of Umoja’s leadership team will also be available for one-on-one meetings.
  • If you are interested in a meeting, please reach out via the H.C. Wainwright Conference Platform.

Umoja Biopharma to Participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech Conference

Retrieved on: 
Thursday, February 22, 2024
Umoja, Evercore, Autoimmunity, Fireside, Immunotherapy, Conference

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced that the company will participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech Conference, taking place virtually on February 28-29, 2024.

Key Points: 
  • SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced that the company will participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech Conference, taking place virtually on February 28-29, 2024.

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Retrieved on: 
Tuesday, January 16, 2024
DISCO, Stanford University, Patient, Sofinnova, Therapy, Research, Colorectal cancer, Umoja, University, Map, COYA, Pfizer, Drug discovery, EVP, Roche, Spacecraft, SCLC, ETH, BMS, Protein, CDO, Genome, Bayer, Doctor of Philosophy, Proteomics, Merck Group, Carcinoma

Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.

Key Points: 
  • Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.
  • COLOGNE, Germany and ZURICH, Jan. 16, 2024 /PRNewswire/ -- DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth today.
  • The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing of EUR 20 million and is backed by a world leading investor syndicate, including Sofinnova Partners, which led the round, Panakes Partners, M Ventures and AbbVie Ventures.
  • Roman Thomas, Founder and Chief Executive Officer, at DISCO Pharmaceuticals, said: "Today, we are launching DISCO Pharmaceuticals and its breakthrough technology after a decade of research by our exceptional team.

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Retrieved on: 
Tuesday, January 16, 2024
DISCO, Stanford University, Patient, Sofinnova, Therapy, Research, Colorectal cancer, Umoja, University, Map, COYA, Pfizer, Drug discovery, EVP, Roche, Spacecraft, SCLC, ETH, BMS, Protein, CDO, Genome, Bayer, Doctor of Philosophy, Proteomics, Merck Group, Carcinoma

Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.

Key Points: 
  • Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.
  • COLOGNE, Germany and ZURICH, Jan. 16, 2024 /PRNewswire/ -- DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth today.
  • The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing of EUR 20 million and is backed by a world leading investor syndicate, including Sofinnova Partners, which led the round, Panakes Partners, M Ventures and AbbVie Ventures.
  • Roman Thomas, Founder and Chief Executive Officer, at DISCO Pharmaceuticals, said: "Today, we are launching DISCO Pharmaceuticals and its breakthrough technology after a decade of research by our exceptional team.

Umoja Foundation’s charity NFT collection that supports Ugandan orphans mints November 28 for Giving Tuesday

Retrieved on: 
Thursday, December 21, 2023
Ethereum, Collection, MoneyGram, USD, Walking, PayPal, Suicidal ideation, Blockchain, Human, Non-fungible token, Medicine, Education, Clothing, Cash, Food, NFT, Cryptocurrency, Umoja

The Umoja Foundation is pulling charity work out of the stone age and onto its future path, immortalized on the blockchain.

Key Points: 
  • The Umoja Foundation is pulling charity work out of the stone age and onto its future path, immortalized on the blockchain.
  • New York | November 15, 2023 03:12 PM Eastern Standard Time
    Umoja Foundation , the philanthropic web3 project, has unveiled their first collection of 6,050 charity NFTs set to mint on November 28 for Giving Tuesday.
  • Ideated by the very people the project supports, each Umoja charity NFT supports the orphans and surrounding needy community of Dasom Ministries Orphanage in Uganda.
  • Future collections will include animated and physical NFTs, and support wider communities in Uganda, Africa, and beyond.

Umoja Biopharma Announces Opening of Development and Manufacturing Facility in Louisville, Colorado

Retrieved on: 
Thursday, October 19, 2023
Senior, Growth, Hematological Cancer Research Investment and Education Act, Patient, Doctor of Philosophy, Interface (computing), Pharmaceutical industry, Umoja

SEATTLE, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, announced today the opening of its new development and manufacturing facility, The Colorado Laboratory & Innovative Manufacturing Building (The CLIMB) in Louisville, Colo.

Key Points: 
  • SEATTLE, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, announced today the opening of its new development and manufacturing facility, The Colorado Laboratory & Innovative Manufacturing Building (The CLIMB) in Louisville, Colo.
  • The facility is designed to accelerate the development of Umoja’s therapeutic candidates.
  • The Company anticipates its first manufacturing run of clinical material in the first quarter of 2024.
  • We are thrilled to be a part of this vibrant and dynamic community in Colorado as we work together to bring life-changing therapies to patients and their families.”

Umoja Biopharma’s VivoVec Platform Presents Encouraging Proof-of-Concept Data in Ongoing Non-Human Primate Study at the 8th CAR-TCR Summit

Retrieved on: 
Friday, September 1, 2023
CD20, Cell, CAR, Discovery, Hematological Cancer Research Investment and Education Act, Animal, Patient, Cancer, NHP, MDF, Vaccine, Umoja

SEATTLE, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced new data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the Company’s VivoVec™ platform technology at the 8th CAR-TCR Summit taking place in Boston, MA, August 29 - September 1, 2023.

Key Points: 
  • The data include results from the first four NHPs treated in an ongoing study and demonstrate rapid and efficient in vivo generation of anti-CD20-targeting CAR T cells following a single infusion of Umoja’s multidomain fusion (MDF) VivoVec particles without the administration of pre-conditioning lymphodepleting chemotherapy.
  • Additionally, these data suggest that the CAR T cells generated in vivo demonstrated on-target activity and persistent T cell memory.
  • “These data highlight the incredible progress Umoja has made and the potential of our unique delivery platform to effectively generate CAR T cells in vivo.
  • Beyond the generation of CAR T cells, we are observing on-target CAR activity and durable cell survival, which could potentially translate to significant clinical benefits for patients.

Ozette Technologies Announces New Collaboration with Umoja Biopharma to Accelerate Biomarker Discovery in Preclinical Studies

Retrieved on: 
Wednesday, June 21, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Partnership, Drug development, Therapy, Senior, Research fellow, Umoja, CAR, Hematological Cancer Research Investment and Education Act, Patient, Machine learning, Immune system, Biology, R, News, Vaccine

Ozette Technologies, Inc. , a technology-driven life sciences company, today announced its collaboration with Umoja Biopharma, Inc. , a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers.

Key Points: 
  • Ozette Technologies, Inc. , a technology-driven life sciences company, today announced its collaboration with Umoja Biopharma, Inc. , a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers.
  • Umoja will use Ozette’s AI-powered single-cell technology for their preclinical studies.
  • As part of this work, the Ozette Platform™ will be used to provide research and development (R&D) support and evaluate biomarker endpoints from preclinical tumor-bearing, humanized mouse models.
  • Humanized mouse models are often deployed in preclinical studies as a tool for modeling human immune responses in the evaluation of potential therapeutics and treatment effects before first-in-human studies.

Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity

Retrieved on: 
Wednesday, May 17, 2023
UB, Gene, Drug discovery, CAR, Date, Investigational New Drug, Hematological Cancer Research Investment and Education Act, Annual general meeting, Cell, American Society of Gene and Cell Therapy, Neoplasm, Surface, MDF, Society, Vaccine, Medical imaging, Umoja, IND

SEATTLE, May 17, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced the presentation of new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting demonstrating potent in vivo CAR T cell generation and robust anti-tumor activity using its VivoVec™ platform.

Key Points: 
  • We look forward to bringing our product candidates to the clinic in the coming year.”
    Umoja’s oral and poster presentations highlight preclinical data demonstrating efficient in vivo CAR T cell generation and anti-tumor activity using its off-the-shelf surface-engineered lentiviral VivoVec platform.
  • Specifically, the preclinical data highlight advancements made in vector design by incorporating a multidomain fusion (MDF) protein that improves activity via multiple routes of administration.
  • MDF VivoVec particles demonstrate improved anti-tumor response in vivo and at a lower dose compared to particles containing separate costimulatory molecules.
  • MDF-engineered VivoVec particles delivered using Lupagen’s extracorporeal system generate functional CAR T cells in vivo that mediate durable anti-tumor responses in preclinical tumor xenograft models.

Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors

Retrieved on: 
Wednesday, December 14, 2022
Bristol Myers Squibb, Immunotherapy, Bayer, Enlightenment, Long Island University, Clinical trial, Pharmacology, Concordia University, Marketing, Iclingas, Seattle, Staten Island University Hospital, Drug development, REPL, Toxicology, Research, Chair, Biology, Purdue University, COVID-19, Social disruption, Patient, Therapy, Pharmaceutical industry, Management, Sanofi, Umoja, Pfizer

“We are extremely pleased to have Dieter join Umoja as the Chair of our Board of Directors.

Key Points: 
  • “We are extremely pleased to have Dieter join Umoja as the Chair of our Board of Directors.
  • Dieter Weinand added, “With the ENLIGHTen clinical trial underway and Umoja positioned to advance its platforms through multiple collaborations in 2022, this is an exciting time to be joining the Company.
  • He is currently Chairman of the Board of Replimune (REPL), Member of the Board of Directors of Reunion Neuroscience (REUN), Chairman of the Board of Directors of ForeBio, Chairman of the Board of Mnemo, and Executive Chairman of the Board of ZielBioPharma.
  • This press release contains forward-looking statements about Umoja Biopharma, Inc. (the “Company,” “we,” “us,” or “our”).